These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
580 related articles for article (PubMed ID: 16556028)
1. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Uren A; Toretsky JA Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028 [TBL] [Abstract][Full Text] [Related]
2. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors. Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687 [TBL] [Abstract][Full Text] [Related]
3. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944 [TBL] [Abstract][Full Text] [Related]
4. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage. Ban J; Siligan C; Kreppel M; Aryee D; Kovar H Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154 [TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. Ginsberg JP; de Alava E; Ladanyi M; Wexler LH; Kovar H; Paulussen M; Zoubek A; Dockhorn-Dworniczak B; Juergens H; Wunder JS; Andrulis IL; Malik R; Sorensen PH; Womer RB; Barr FG J Clin Oncol; 1999 Jun; 17(6):1809-14. PubMed ID: 10561219 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877 [TBL] [Abstract][Full Text] [Related]
7. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673 [TBL] [Abstract][Full Text] [Related]
8. A molecular function map of Ewing's sarcoma. Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404 [TBL] [Abstract][Full Text] [Related]
9. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923 [TBL] [Abstract][Full Text] [Related]
10. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047 [TBL] [Abstract][Full Text] [Related]
11. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692 [TBL] [Abstract][Full Text] [Related]
12. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells. Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505 [TBL] [Abstract][Full Text] [Related]
13. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Abaan OD; Levenson A; Khan O; Furth PA; Uren A; Toretsky JA Oncogene; 2005 Apr; 24(16):2715-22. PubMed ID: 15782144 [TBL] [Abstract][Full Text] [Related]
14. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Aryee DN; Niedan S; Kauer M; Schwentner R; Bennani-Baiti IM; Ban J; Muehlbacher K; Kreppel M; Walker RL; Meltzer P; Poremba C; Kofler R; Kovar H Cancer Res; 2010 May; 70(10):4015-23. PubMed ID: 20442286 [TBL] [Abstract][Full Text] [Related]
16. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. Lai R; Navid F; Rodriguez-Galindo C; Liu T; Fuller CE; Ganti R; Dien J; Dalton J; Billups C; Khoury JD J Pathol; 2006 Apr; 208(5):624-32. PubMed ID: 16463269 [TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Bachmaier R; Aryee DN; Jug G; Kauer M; Kreppel M; Lee KA; Kovar H Oncogene; 2009 Mar; 28(9):1280-4. PubMed ID: 19151750 [TBL] [Abstract][Full Text] [Related]
20. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Kinsey M; Smith R; Lessnick SL Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]